InnoCare Pharma (OTCMKTS:INCPF – Get Free Report) will likely be announcing its resultson Monday, August 24th. Analysts expect InnoCare Pharma to announce earnings of ($0.0126) per share and revenue of $101.70 million for the quarter.
InnoCare Pharma Price Performance
InnoCare Pharma stock opened at $1.55 on Friday. The firm’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $1.60. InnoCare Pharma has a 1-year low of $1.55 and a 1-year high of $2.31.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley upgraded InnoCare Pharma to an “overweight” rating in a research note on Thursday, May 28th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy”.
About InnoCare Pharma
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Recommended Stories
- Five stocks we like better than InnoCare Pharma
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
